First-line immunotherapy in PD-L1-high non-small cell lung cancer: indirect treatment comparison of pembrolizumab and atezolizumab

被引：0
|
作者：
Griesinger, F. [1 ]
Sibbe, M. S. [2 ]
Hieke-Schulz, S. [2 ]
Buhck, H. [2 ]
Reinmuth, N. [3 ]
Rittmeyer, A. [4 ]
机构：
[1] Pius Hosp Univ Med Oldenburg, Oldenburg, Germany
[2] Roche Pharma AG, Grenzach Wyhlen, Germany
[3] Asklepios Fachkliniken, Munich, Germany
[4] Lungenfachklin Immenhausen, Immenhausen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P448
引用
收藏
页码：227 / 228
页数：2
相关论文
共 50 条
  • [1] Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status
    Alessi, Joao, V
    Ricciuti, Biagio
    Jimenez-Aguilar, Elizabeth
    Hong, Fangxin
    Wei, Zihan
    Nishino, Mizuki
    Plodkowski, Andrew J.
    Sawan, Peter
    Luo, Jia
    Rizyi, Hira
    Carter, Brett W.
    Heymach, John, V
    Altan, Mehmet
    Hellmann, Matthew
    Awad, Mark
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [2] Immunophenotypic correlates and response to first-line pembrolizumab among elderly patients with PD-L1-high (≥ 50%) non-small cell lung cancer.
    De Castro Barrichello, Adriana Paula
    Alessi, Joao Victor Machado
    Ricciuti, Biagio
    Pecci, Federica
    Vaz, Victor R.
    Lamberti, Giuseppe
    Turner, Madison M.
    Pfaff, Kathleen L.
    Rodig, Scott J.
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Pembrolizumab for the first-line treatment of non-small cell lung cancer
    Ninomiya, Kiichiro
    Hotta, Katsuyuki
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1015 - 1021
  • [4] Pembrolizumab mono versus Pembrolizumab plus Chemotherapy as first-line Palliative Therapy for PD-L1-high positive Non-small Cell Lung Cancer: a Two-center Study
    Olive, E.
    Frost, N.
    Grohe, C.
    PNEUMOLOGIE, 2022, 76 : S93 - S93
  • [5] Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small-cell lung cancer and a poor performance status.
    Alessi, Joao Victor Machado
    Ricciuti, Biagio
    Aguilar, Elizabeth Jimenez
    Hong, Fangxin
    Wei, Zihan
    Nishino, Mizuki
    Plodkowski, Andrew J.
    Sawan, Peter
    Luo, Jia
    Rizvi, Hira
    Carter, Brett W.
    Heymach, John
    Altan, Mehmet
    Hellmann, Matthew David
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Non-small cell Lung Cancer Atezolizumab is now also approved for First-Line Monotherapy for high PD-L1 Expression
    Vetter, Christine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (05)
  • [7] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
    Zhou, Yixin
    Lin, Zuan
    Zhang, Xuanye
    Chen, Chen
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [8] Atezolizumab in a first-line setting in non-small-cell lung cancer with high PD-L1 expression
    Dugage, Matthieu Roulleaux
    Brosseau, Solenn
    BULLETIN DU CANCER, 2021, 108 (10) : 904 - 906
  • [9] Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression
    Ikezawa, Yasuyuki
    Mizugaki, Hidenori
    Morita, Ryo
    Tateishi, Kazunari
    Yokoo, Keiki
    Sumi, Toshiyuki
    Kikuchi, Hajime
    Kitamura, Yasuo
    Nakamura, Atsushi
    Kobayashi, Maki
    Aso, Mari
    Kimura, Nozomu
    Yoshiike, Fumiaki
    Furuta, Megumi
    Tanaka, Hisashi
    Sekikawa, Motoki
    Hachiya, Tsutomu
    Nakamura, Keiichi
    Shimokawa, Mototsugu
    Oizumi, Satoshi
    CANCER SCIENCE, 2022, 113 (06) : 2109 - 2117
  • [10] Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
    Martinez, Pablo
    Peters, Solange
    Stammers, Timothy
    Soria, Jean-Charles
    CLINICAL CANCER RESEARCH, 2019, 25 (09) : 2691 - 2698
12345